Volume 15 - Issue 1 - January, 2004

The Anticoagulant Therapy with Bivalirudin to Assist in the Performance of Percutaneous Coronary Intervention in Patients with

Kenneth W. Mahaffey, MD,* Bruce E. Lewis, MD,† Nancy M. Wildermann, BA,* Scott D. Berkowitz, MD,*‡ Renee M. Oliverio, RN,* Mark A. Turco, MD,§ Yoseph Shalev, MD,§§ Peter Ver Lee, MD,*** Jay H. Traverse, MD,‡‡ A. Ralph Rodriguez, MD,** E. Magnus Ohman, MD,†† Robert A. Harrington, MD,* Robert M. Califf, MD,* for the ATBAT Investigators

Heparin-induced thrombocytopenia (HIT) is infrequent and often goes unrecognized. It occurs in ~1% to 5% of the patients given unfractionated heparin,1 about 25–50% of whom will develop HIT with thrombotic syndrome (HITTS).2 Morbidity and mortality are high, and more than 50% of patients suffering thrombotic complications will die.3 Patients with recognized HIT may require anticoagulation for acute coronary syndromes (ACS) or percutaneous coronary intervention (PCI), thus presenting a clinical challenge given the limited alternatives for anticoagulation treat...

Hemostasis in the Era of the Chronic Anticoagulated Patient

Bonnie Weiner, MD, *Thomas Fischer, PhD, †Sergio Waxman, MD

Mechanisms for Hemostasis and Comparative Efficacy

The technology to produce poly-N-acetylglucosamine (pGlcNAc) polymer is based on a biomaterial that is derived in a fiber form from aseptic cultures of a marine microalgae diatom. Once isolated and purified, the high quality, pure material is subject to rigorous quality control and quality assurance. The end product can be formulated as patches, lyophilized patches, gels, microspheres, and foams. The isolation of pGlcNAc fibers provides the source of the material for the manufacture of the Syvek Patch® (Marine Polymer Technologies, Danvers...

Use of Lepirudin During Percutaneous Vascular Interventions in Patients with Heparin-Induced Thrombocytopenia

Kevin Cochran, MD, Tony J. DeMartini, MD, Bruce E. Lewis, MD, James O’Brien, RN, Lowell H. Steen, MD, Eric D. Grassman, MD, PhD, Ferdinand Leya, MD

Percutaneous coronary intervention is a common procedure, with over 750,000 interventions performed in the United States per year. Balloon inflation and stent deployment cause endothelial injury and plaque disruption, leading to platelet activation, thrombin generation and an inflammatory response. Aspirin, clopidogrel, platelet glycoprotein (GP) IIb/IIIa receptor inhibitors and unfractionated or low-molecular weight heparin are routinely used to counteract the effects of thrombin and the stimulated platelet population. The GP IIb/IIIa inhibitors block the final common pathway of platelet acti...

Thrombolytic Therapy for Right Atrial and Pulmonary Embolus

David G. Rizik, MD, Bernard J. Villegas, MD, Andre P. Bouhasin, MD, Richard Levinson, MD

A 68-year-old male with a history of hypertension presented to the emergency department with acute onset pain and severe swelling of the left lower extremity. Pleuritic chest discomfort was also noted. He had been traveling by automobile from Canada to the Desert Southwest for 3 days and admitted to very little activity during this period. Physical exam was notable for a swollen, painful left calf with an easily reproducible Homan’s sign. He was noted to have a murmur of tricuspid regurgitation. Shortly after initial evaluation, he became visibly dyspneic with oxygen saturations of 89–90% ...

PCI Options in Heparin-Induced Thrombocytopenia

George Dangas, MD, PhD, and Eugenia Nikolsky, MD, PhD

Heparin-induced thrombocytopenia (HIT) is a rather rare complication of heparin therapy, but may occasionally lead to devastating or even life-threatening complications. HIT is more frequent after therapy with unfractionated than low molecular weight heparin. The inherent problem of prothrombosis in HIT can be a major obstacle in patients who need therapy with percutaneous coronary interventions (PCI), especially with stent implantation. This is due to the iatrogenic plaque disruption and promotion of an endovascular thrombosis process during PCI, and the added risk of stent thrombosis. Theref...

Treatment of In-Stent Restenosis in a Gastroepiploic Artery Coronary Bypass Graft with Brachytherapy

William B. Hillegass, MD, MPH, Gilbert J. Zoghbi, MD, Anand Pandey, MD, Vijay K. Misra, MD, Gregory D. Chapman, MD, Brigitta C. Brott, MD

Since it was first used in 1984 and reported in 1987,1,2 the right gastroepiploic artery (RGEA) has emerged as an effective third or isolated arterial conduit for complete arterial bypass grafting or for use in cases of limited graft numbers or poor quality vein for grafts.3–5 The RGEA can be used as a pedicled or free graft with or without cardiopulmonary bypass.6 The RGEA grafts are superior to vein grafts, with > 95% short-term patency rates and actuarial 5-year patency rates of 80–85%,7–9 with a 5-year survival rate > 92%.5,9 Ischemic events related to pedicled RGEA grafts result fro...

Benefits of Cutting Balloon Before Stenting

1David G. Rizik, MD, 2Jeffrey P. Popma, MD, 3Martin B. Leon, MD, 4Gary S. Mintz, MD, 5Bonnie Weiner, MD, 6Eric Cohen, MD, 4Alexandra J. Lansky, MD, 7Antoine M. Adem, MD, Andre P. Bouhasin, MD, 7Carol Wojciechowski, RN, 8Neil J. Weissman, MD

Cutting balloon (CB) technology combines the features of microsurgical incision with balloon dilation to treat atherosclerotic lesions. The CB has a non-compliant dilation balloon with microsurgical blades (atherotomes) attached to the outer surface. The cutting blades serve to radially incise the atherosclerotic lesion prior to balloon expansion. Linear incisions made by the blades facilitate expansion of the atherosclerotic lesion at lower inflation pressures, resulting in less barotrauma-related injury to the vessel wall.1 In addition, the symmetric and orderly disruption of the plaque lesi...

Percutaneous Coronary Artery Stenting of an Anomalous Right Coronary Artery with High Anterior Takeoff Using Standard Size 7

*†Benjamin I. Lee, MD, ‡Herman C. Gist Jr., MD, †Edward I. Morris, MD

The anomalous right coronary artery (RCA) with high anterior takeoff is an uncommon, yet technically difficult vessel to cannulate, moreover to intervene upon. The high anterior location of the anomalous ostium is often difficult to reach with standard catheters and because of the immediate posterior direction of the vessel, percutaneous intervention requires more secure guiding catheter support compared to the normally located RCA. Several published case studies have described the technical difficulties associated with balloon angioplasty and stenting of anomalous RCAs and successful outcomes...

Influence of Frequency of Stenting on Acute and One-Year Follow-up Results

Haresh Mehta, MD, Renate Hotz, MD, Stephan Windecker, MD, Franz R. Eberli, MD, Bernhard Meier, MD

Stents were introduced as a bail-out therapy for threatened abrupt closure1–5 following plain balloon coronary angioplasty. They were subsequently demonstrated to lower the restenosis rates in selected patient populations.6–8 The smooth appearance of the vessel after stenting has seduced the interventionist. The stenting rates are reported to be approximately 70%9 and move toward 100%. Stenting, albeit an essential and effective tool, has downsides such as stent thrombosis (still a concern in spite of newer antiplatelet drugs) and intricate in-stent restenosis. The long and diffuse variety...

Editor's Message - November 2003

Richard E. Shaw, PhD, FACC

This issue of the Journal of Invasive Cardiology coincides with the Annual Scientific Sessions of the American Heart Association and includes original research articles, case reports, a special review, two CME offerings and articles from the journal special sections “the Electrophysiology Corner,” “Clinical Decision Making” and “Clinical Images.”

The first research article, submitted by Dr. Kenneth Mahaffey from the Duke Clinical Research Institute on behalf of the ATBAT investigators, is a report of a multicenter trial examining the role of bivalirudin as adjunct therapy for ...

Editorial Staff
  • Executive Officer
    Laurie Gustafson
  • Production
    Elizabeth Vasil
  • National Account Manager
    Jeff Benson
  • Senior Account Director
    Carson McGarrity
  • Special Projects Editor
    Amanda Wright
Editorial Correspondence
  • Laurie Gustafson, Executive Editor, JIC
  • HMP Communications, 83 General Warren Blvd

    Suite 100, Malvern PA 19355
  • Telephone: (248)360-2777 or

    (610)560-0500, ext. 121

    Fax: (610)560-0501.
  • E-mail: lgustafson@hmpcommunications.com

Back to top